219138-24-6
219138-24-6
Chemical Structure
p38 MAPK-IN-4
- CAS No.: 219138-24-6
- Formula:C20H13ClFN3O
- Molecular Weight:365.79
IUPAC Name: 2-(4-chlorophenyl)-4-(4-fluorophenyl)-5-(pyridin-4-yl)-1,2-dihydro-3H-pyrazol-3-one
InChIKey: DZFBYHUKZSRPHU-UHFFFAOYSA-N
SMILES: O=C1N(C2=CC=C(Cl)C=C2)NC(C3=CC=NC=C3)=C1C4=CC=C(F)C=C4
Biological Activity: p38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor with an IC50 of 35 nM[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
p38 MAPK-IN-4 | 98.69% | p38 MAPK-IN-4 (compound 6) is a p38 MAPK inhibitor with an IC50 of 35 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Adezmapimod (Standard) | 98.69% | Adezmapimod (Standard) is the analytical standard of Adezmapimod. This product is intended for research and analytical applications. Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC50s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC50s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod can inhibit p38 MAPK and lead to the inhibition of downstream HSP27 phosphorylation. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB 202190 hydrochloride (Standard) | ≥98% | SB 202190 (hydrochloride) (Standard) is the analytical standard of SB 202190 (hydrochloride). This product is intended for research and analytical applications. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity. SB202190 hydrochloride induces autophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB 202190 (Standard) | ≥98% | SB 202190 (Standard) is the analytical standard of SB 202190. This product is intended for research and analytical applications. SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits. SB202190 induces autophagy. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PD 169316 (Standard) | 98.03% | PD 169316 (Standard) is the analytical standard of PD 169316 (HY-10578). This product is intended for research and analytical applications. PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor, with IC50 of 89 nM. PD169316 selectively inhibits the kinase activity of the phosphorylated p38 without hindering upstream kinases to phosphorylate p38. PD169316 shows antiviral activity against Enterovirus71. PD169316 shows antiviral activity against Enterovirus71. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
L-167307 | L-167307 is an effective pyrrole-based p38 kinase inhibitor that can reduce secondary paw swelling in rat adjuvant-induced arthritis models. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
p38 MAPK-IN-8 | p38 MAPK-IN-8 (Compound 8) is an orally active, potent and selective p38 mitogen-activated protein kinase (p38 MAPK) inhibitor. p38 MAPK-IN-8 is promising for research of inflammatory responses, autoimmune diseases, and cancer. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucagon receptor antagonist-8 | Glucagon receptor antagonist-8 (Compound 1) is a human glucagon receptor and p38 mitogen-activated protein (MAP) kinase antagonist, with IC50s of 0.27 μM and 0.16 μM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucagon receptor antagonist-9 | Glucagon receptor antagonist-9 (compound 13) is a potent glucagon receptor antagonist with a pIC50 of 7.000. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucagon receptor antagonist-10 | Glucagon receptor antagonist-10 (Compound 11) is a glucagon receptor antagonist with a pIC50 of 7.154. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Glucagon receptor antagonist-11 | Glucagon receptor antagonist-11 (Compound 14) is a glucagon receptor antagonist with a pIC50 of 6.677. Glucagon receptor antagonist-10 can be used in studies of glucose homeostasis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
